FINERENONE ADDED TO RAS/SGLT2 BLOCKADE FOR NON-DIABETIC CHRONIC KIDNEY DISEASE: RESULTS OF A PRECLINICAL DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL

被引：0
|
作者：
Zhu, Zhihui [1 ]
Kusunoki, Yoshihiro [1 ]
Rosenkranz, Karoline [1 ]
Li, Chenyu [1 ]
Klaus, Martin [1 ]
Gross, Oliver [2 ]
Angelotti, Maria Lucia [3 ]
Cirillo, Luigi [3 ]
Romagnani, Paola [3 ]
Buelow, Roman David [4 ]
Boor, Peter [4 ]
Anders, Hans-Joachim [1 ]
机构：
[1] Hosp Ludwig Maximilians Univ, Dept Med 4, Div Nephrol, Munich, Germany
[2] Univ Med Ctr Goettingen, Clin Nephrol & Rheumatol, Gottingen, Germany
[3] Univ Florence, Dept Biomed Expt & Clin Sci Maria Serio, Florence, Italy
[4] RWTH Univ Hosp Aachen, Inst Pathol, Aachen, Germany
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
4534
引用
收藏
页码：I51 / I52
页数：2
相关论文
共 50 条
  • [1] Finerenone Added to RAS/SGLT2 Blockade for Non-Diabetic Chronic Kidney Disease. Results of a Preclinical Double- Blinded Randomized Controlled Trial
    Zhu, Zhihui
    Anders, Hans-Joachim
    CIRCULATION, 2023, 148
  • [2] SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
    Podesta, Manuel Alfredo
    Sabiu, Gianmarco
    Galassi, Andrea
    Ciceri, Paola
    Cozzolino, Mario
    BIOMEDICINES, 2023, 11 (02)
  • [3] Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice
    Zhu, Zhihui
    Rosenkranz, Karoline A. T.
    Kusunoki, Yoshihiro
    Li, Chenyu
    Klaus, Martin
    Gross, Oliver
    Angelotti, Maria-Lucia
    Antonelli, Giulia
    Cirillo, Luigi
    Romagnani, Paola
    Bouteldja, Nassim
    Sadr, Alireza Vafaei
    Buelow, Roman D.
    Boor, Peter
    Anders, Hans-Joachim
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 34 (09): : 1513 - 1520
  • [4] SGLT2 inhibitors in non-diabetic kidney disease
    Tesar, Vladimir
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2022, 31 (02): : 105 - 107
  • [5] Comment on "The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease"
    Chen, I. -Wen
    Chang, Li-Chen
    Hung, Kuo-Chuan
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2024, 56 (06) : 2115 - 2116
  • [6] Comment on “The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease”
    I.-Wen Chen
    Li-Chen Chang
    Kuo-Chuan Hung
    International Urology and Nephrology, 2024, 56 : 2115 - 2116
  • [7] Extending the ambit of SGLT2 inhibitors beyond diabetes: a review of clinical and preclinical studies on non-diabetic kidney disease
    Nayak, Saurabh
    Rathore, Vinay
    Bharati, Joyita
    Sahu, Kamal Kant
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (12) : 1513 - 1526
  • [8] Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease
    Ahluwalia, Tarunveer S.
    Ronkko, Teemu K. E.
    Eickhoff, Mie K.
    Curovic, Viktor Rotbain
    Siwy, Justyna
    Eder, Susanne
    Denicolo, Sara
    Mayer, Gert
    Mischak, Harald
    Rossing, Peter
    Persson, Frederik
    KIDNEY INTERNATIONAL REPORTS, 2024, 9 (02): : 334 - 346
  • [9] EFFECTS OF TANGSHEN FORMULA ON PATIENTS WITH TYPE 2 DIABETIC KIDNEY DISEASE: A MULTICENTER DOUBLE-BLINDED RANDOMIZED PLANCEBO-CONTROLLED TRIAL
    Li Ping
    Chen Yiping
    Liu Jianping
    Hong Jing
    Deng Yueyi
    Yang Fang
    Jin Xiuping
    Gao Jing
    Li Jing
    Fang Hui
    Liu Geling
    Shi Liping
    Du Jinhang
    Yan Meihua
    Wen Yumin
    Yang Wenying
    NEPHROLOGY, 2014, 19 : 47 - 47
  • [10] SGLT-2 Inhibitors and Nephroprotection in Patients with Diabetic and Non-diabetic Chronic Kidney Disease
    Sarafidis, Pantelis
    Pella, Eva
    Kanbay, Mehmet
    Papagianni, Aikaterini
    CURRENT MEDICINAL CHEMISTRY, 2023, 30 (18) : 2039 - 2060
12345